Clinical Trial

Beacon Therapeutics Treats First Patient in LANDSCAPE Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)

LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterallyLONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon…

7 days ago

Genflow Completes Dosing Phase of Canine Gene Therapy Trial

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET…

1 week ago

President Trump Cleaning Up Biden’s Marijuana Mess – MMJ Preparing to Move FDA Huntington’s Cannabis Trials Forward

Trump Prepares to Clean Up Biden's "Do-Nothing" Marijuana Mess: Why MMJ International Holdings Takes the Lead in a Pharmaceutical Cannabis…

1 week ago

Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology…

1 week ago

Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI

Rushing Headlong: Health IT's Legacy and the Road to Responsible AI by Dr. S. Yin Ho is an indispensable book…

1 week ago

Apyron Pioneering Next Generation Pain Management Solutions

Atlanta, Georgia--(Newsfile Corp. - December 15, 2025) - Apyron, Inc. is a medical technology company with a product portfolio designed…

1 week ago

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has demonstrated significant improvement in depression…

1 week ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) -…

1 week ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s mNEXSPIKE (COVID-19 Vaccine, mRNA)

mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial…

1 week ago